Data from the phase 1/2 LIBRETTO-001 trial support the FDA approval of selpercatinib in patients with RET fusion-positive thyroid cancer.
Approval Alert | Selpercatinib in RET+ Thyroid Cancer
Data from the phase 1/2 LIBRETTO-121 trial led to the approval of selpercatinib in pediatric RET-mutant thyroid cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss
2
Porustobart/Tislelizumab Elicits Responses in MSS Metastatic Colorectal Cancer
3
An Oncodermatologist’s Perspective on Dermatological Toxicities in Breast Cancer
4
What Path to Approval Has Dasatinib Taken in CML/ALL?
5
